Khure Health develops a precision medicine platform that harnesses clinical data, enabling physicians to rapidly screen and identify patients with rare diseases and facilitate more personalized treatment.
According to the press statement, this strategic acquisition will enhance MCI’s data analytics offering through Khure’s continued work with pharmaceutical and medical device companies in North America, Europe, and Japan.
According to Khure Health, its platform using precision medicine, clinical data, machine learning, and artificial intelligence makes it easier for physicians to identify and treat rare and specialty conditions.
“Linking Khure’s functional clinical intelligence platform to our existing databases is an integral step in redefining the way that technology is used in MCI’s healthcare network. Identifying undiagnosed patients with rare diseases empowers primary care doctors with the essential tools and technology to take meaningful steps forward towards a future of preventive care,” said Dr. Alexander Dobranowski MD., CEO of MCI.
Alexander Dobranowski added: “This is also a very exciting time with Khure recently launching its new clinical trial offering that utilizes its AI-enabled clinical intelligence platform to accelerate patient recruitment for clinical trials and speed scientific discovery. This platform will help bring much-needed new precision medicines and clinical knowledge to benefit patients in need faster than ever before.”
Sixty-three digital health companies were acquired in Q1 2021, compared to 52 M&A transactions in Q4 2020. Halma, a British group of safety equipment companies that make products for hazard detection and life protection, acquired PeriGen, which uses an artificial intelligence-enabled clinical decision support tool for obstetrics, for $58 million in cash.